What is Nanjing Pharmaceutical Group Company Limited's (600713.SS) StockRank?

MoatMap's StockRank for Nanjing Pharmaceutical Group Company Limited (600713.SS) is 77/100, with a Buy signal. This is a composite score combining Quality (45), Value (66), and Momentum (59) factor ranks across MoatMap's 20,000+ stock universe.

Does Nanjing Pharmaceutical Group Company Limited have an economic moat?

Nanjing Pharmaceutical Group Company Limited (600713.SS) has a Quality factor score of 45/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Nanjing Pharmaceutical Group Company Limited a buy, hold, or sell?

MoatMap's current signal for Nanjing Pharmaceutical Group Company Limited (600713.SS) is Buy, based on a StockRank of 77/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Nanjing Pharmaceutical Group Company Limited in?

Nanjing Pharmaceutical Group Company Limited (600713.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - General industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

600713.SS

BUY

Nanjing Pharmaceutical Group Company Limited · Healthcare · China · $977M · Avg Vol: $8M/d

StockRank

Get insider-trade alerts

P/E (TTM)

12.4x

ROE

10.1%

D/E

1.6x

Dividend %

3.4%

COMPANY DESCRIPTION

Nanjing Pharmaceutical Group Company Limited is a leading regional pharmaceutical distributor and retailer, primarily operating in Jiangsu, Anhui, and Fujian provinces. The company maintains a robust competitive moat through its extensive network of hospital supply chains, retail pharmacies, and state-of-the-art cold-chain logistics centers. Its close integration with public healthcare institutions and advanced third-party logistics capabilities ensure stable, volume-driven revenue streams.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM
Revenue	7.4B	7.9B	7.9B	8.1B	3.1%	8.0B
EPS	0.07	0.07	0.06	0.07	0.3%	0.06
Shares	1.3B	1.3B	1.3B	1.3B	-0.1%	1.3B
Debt	826.2M	927.9M	1.2B	859.6M	1.3%	1.9B
Equity	883.7M	947.8M	1.0B	1.1B	6.2%	—
Op CF	-100.5M	280.8M	314.6M	13.5M	-78.1%	-221.3M
Inv CF	-8.7M	-25.5M	-82.8M	-28.8M	—	—
Fin CF	68.7M	-170.4M	-123.7M	-63.5M	—	—

Loading 1Y...

PRICE (1Y)+1.6%

SMA 50SMA 200

$0.7497

RSI (14)

58.8

52W High

$0.9476

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

11.4%77.2

ROE

10.1%72.1

GP/Assets

10.8%27.7

Op. Margin

2.8%50.5

FCF/Assets

-4.9%33.5

Piotroski

548.9

Int. Cover

4.7x50.3

D/E Ratio

1.56x8.5

Current Ratio

1.45x24.6

Value

P/E (TTM)

12.4x82.3

EV/EBITDA

12.4x55.9

P/FCF

—N/A

P/B

0.9x85.9

P/S

0.1x99.2

Div Yield

3.4%73.6

Momentum

52W High %

79%65.0

RS 6M

-7%63.7

SMA 50/200

0.98x59.2

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

-2%38.3

FUNDAMENTALS

Market Cap

$977M

P/E (Forward)

—

Gross Margin

6.2%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 600713.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
600713.SS	Nanjing Pharmaceutical Group Company Limited(you)	$977M	77	BUY
000411.SZ	Zhejiang Int'l Group Co.,Ltd.	$749M	83	STRONG BUY
300181.SZ	Zhejiang Jolly Pharmaceutical Co.,LTD	$1.3B	85	STRONG BUY
688710.SS	Shanghai InnoStar Bio-tech Co., Ltd.	$1.3B	62	HOLD
300357.SZ	Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.	$1.6B	61	HOLD
600771.SS	GuangYuYuan Chinese Herbal Medicine Co., Ltd.	$916M	48	HOLD
1666.HK	Tong Ren Tang Technologies Co. Ltd.	$511M	94	STRONG BUY
301507.SZ	Hangzhou Minsheng Healthcare Co., Ltd.	$633M	44	HOLD
1093.HK	CSPC Pharmaceutical Group Limited	$9.7B	74	BUY
002019.SZ	Yifan Pharmaceutical Co., Ltd.	$1.7B	38	HOLD

Peer medians: ROE 4.7% · P/E 28.4x · Gross margin 52.5%

Nanjing Pharmaceutical Group Company Limited (600713.SS) — Stock Score Summary

Nanjing Pharmaceutical Group Company Limited (600713.SS) has a MoatMap StockRank of 77/100 based on Quality (45/100), Value (66/100), and Momentum (59/100) factor scores. The current signal is BUY.

Key Financial Metrics

Price	$0.75
Market Cap	$977M
P/E (TTM)	12.41
Price/Book	0.91
Return on Equity	10.1%
Return on Invested Capital	11.4%
Debt/Equity	155.55
Gross Margin	6.2%
Operating Margin	2.8%
Revenue Growth	-2.8%
Dividend Yield	3.4%
Free Cash Flow	$-228M

Nanjing Pharmaceutical Group Company Limited operates in the Drug Manufacturers - General industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Nanjing Pharmaceutical Group Company Limited’s (600713.SS) StockRank?: MoatMap’s StockRank for Nanjing Pharmaceutical Group Company Limited (600713.SS) is 77/100, with a Buy signal. It is a composite of Quality (45), Value (66), and Momentum (59) factor ranks across MoatMap’s 20,000+ stock universe.
Does Nanjing Pharmaceutical Group Company Limited have an economic moat?: Nanjing Pharmaceutical Group Company Limited (600713.SS) has a Quality factor score of 45/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Nanjing Pharmaceutical Group Company Limited a buy, hold, or sell?: MoatMap’s current signal for Nanjing Pharmaceutical Group Company Limited (600713.SS) is Buy, based on a StockRank of 77/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Nanjing Pharmaceutical Group Company Limited in?: Nanjing Pharmaceutical Group Company Limited (600713.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - General industry (China).